Pancreatic Cancer Research

ResearcherUniversitätsmedizin GöttingenActive in the last 2 years

Frauke Alves

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6258-5409; OpenAlex author ID A5036845188. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 4 papers · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/apha.70183↗
  2. OrganoIDNet: a deep learning tool for identification of therapeutic effects in PDAC organoid-PBMC co-cultures from time-resolved imaging data. Co-author DOI 10.1007/s13402-024-00958-2↗
  3. Anti-Tumor Efficacy of a Mesothelin-Based Nanovaccine in a KPC Orthotopic Mouse Model of Pancreatic Cancer. Co-author DOI 10.3390/vaccines13030314↗
  4. Impact of N-Terminal PEGylation on Synthesis and Purification of Peptide-Based Cancer Epitopes for Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.1021/acsomega.4c02604↗
  5. A Curated Cell Life Imaging Dataset of Immune-enriched Pancreatic Cancer Organoids with Pre-trained AI Models. Last author DOI 10.1038/s41597-024-03631-3↗
  6. KPC-luciferase-expressing cells elicit an anti-tumor immune response in a mouse model of pancreatic cancer. Co-author DOI 10.1038/s41598-024-64053-0↗
  7. Prolonged survival by combination treatment with a standardized herbal extract from Japanese Kampo-medicine (Juzentaihoto) and gemcitabine in an orthotopic tra… Co-author DOI 10.3389/fonc.2024.1454291↗
  8. High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as an Image-Guided Tumor-Selective Drug-Delivery System to Treat Pancreatic Cancer. Last author DOI 10.1002/adma.202305151↗
  9. Crosstalk between tumor acidosis, p53 and extracellular matrix regulates pancreatic cancer aggressiveness. Co-author DOI 10.1002/ijc.34367↗
  10. Three-dimensional analysis of human pancreatic cancer specimens by phase-contrast based X-ray tomography - the next dimension of diagnosis. Co-author DOI 10.1186/s40644-023-00559-6↗
  11. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-021-21774-4↗
  12. Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.3390/cancers12061389↗
  13. Alternating pH landscapes shape epithelial cancer initiation and progression: Focus on pancreatic cancer. Co-author DOI 10.1002/bies.201600253↗
  14. Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/onc.2017.71↗
  15. Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Co-author DOI 10.1002/ijc.30380↗
  16. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Co-author DOI 10.1053/j.gastro.2015.10.020↗
  17. Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ijo.2016.3513↗
  18. Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. Co-author DOI 10.1096/fj.11-182287↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fernanda Ramos‐Gomes · 3 shared papers, 2024–2025 · strength 0.77
  2. M. Andrea Markus · 3 shared papers, 2024–2025 · strength 0.77
  3. Daniele Pereira Ferrari · 3 shared papers, 2024–2025 · strength 0.74
  4. Joanna Napp · 4 shared papers, 2016–2024 · strength 0.66
  5. Nathalia Luisa Carlos Ferreira · 2 shared papers, 2024–2025 · strength 0.52
  6. Ajinkya Kulkarni · 2 shared papers, 2024–2025 · strength 0.52
  7. Stine F. Pedersen · 4 shared papers, 2016–2026 · strength 0.49
  8. Olaf Hardt · 3 shared papers, 2020–2025 · strength 0.48
  9. Omar F. Luna · 2 shared papers, 2024–2025 · strength 0.42
  10. Fernando Alberício · 2 shared papers, 2024–2025 · strength 0.42
  11. Ivana Novak · 3 shared papers, 2016–2026 · strength 0.35
  12. Renata Ialchina · 2 shared papers, 2023–2026 · strength 0.34
  13. Albin Sandelin · 2 shared papers, 2023–2026 · strength 0.34
  14. Diana Pinkert‐Leetsch · 2 shared papers, 2021–2023 · strength 0.32
  15. Jeannine Missbach‐Guentner · 2 shared papers, 2021–2023 · strength 0.32
  16. Pawel Swietach · 2 shared papers, 2017–2026 · strength 0.28
  17. Albrecht Schwab · 2 shared papers, 2017–2026 · strength 0.28
  18. Luis A. Pardo · 2 shared papers, 2017–2026 · strength 0.28
  19. Stephan J. Reshkin · 2 shared papers, 2016–2026 · strength 0.25
  20. Rosa Angela Cardone · 2 shared papers, 2016–2026 · strength 0.25
  21. Janina Henze · 2 shared papers, 2020–2021 · strength 0.24
  22. Wa’el Al Rawashdeh · 2 shared papers, 2020–2021 · strength 0.24
  23. Lena‐Christin Conradi · 1 shared paper, 2025 · strength 0.24
  24. Silke Cameron · 1 shared paper, 2024 · strength 0.23
  25. Volker Ellenrieder · 1 shared paper, 2024 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.